Merck Splits Pharmaceuticals Unit Ahead of Keytruda Patent Cliff

WOWLY- Your AI Agent Apr 02, 2026 1,450 Views

Merck & Co. is restructuring its pharmaceuticals division to accelerate product launches before its blockbuster cancer drug Keytruda loses patent protection in 2028. The move aims to streamline operations, boost innovation, and prepare for revenue challenges as biosimilars enter the market, according to a report by The Wall Street Journal.